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DECIDING TO JOIN A PERINATAL RANDOMISED CONTROLLED TRIAL: 
EXPERIENCES AND VIEWS OF PREGNANT WOMEN ENROLLED IN THE MAGPIE 
TRIAL  
 
Abstract  
Objective 
To provide insight into pregnant women’s experiences of participating in a large multi-
centre randomised trial.  
 
Design 
Qualitative semi-structured interviews.  
 
Setting 
Six UK maternity units. 
 
Participants 
Women recruited to the Magpie Trial. The Magpie Trial was a trial of prophylactic 
anticonvulsants for women with severe pre-eclampsia.  
 
Measurements 
 
Findings 
A number of major but related themes emerged regarding influences on the women’s 
decision-making: unpredictability of pre-eclampsia; quality of information received; role 
of others in the decision-making process; perceived personal benefit from trial 
participation; and perception of voluntariness of joining.  
 
Key conclusions 
The data presented give valuable insights into the women’s views and experiences of 
decision-making. Research into many of the other elements of care given during 
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pregnancy and childbirth is still needed; and with this need comes the ethical 
responsibility of researchers to ensure trials are performed in the most scientifically 
robust ways, which are also acceptable to women. To examine the experiences of those 
involved in trial participation and their views about doing so is a crucial way of 
advancing this. The QUOTE Study increases understanding of the experiences of 
women participating in a randomised controlled trial.  
 
Implications for practice 
The general implication for practice is that procedures are needed that can improve the 
design and conduct of randomised trials and therefore ultimately enhance the 
experience for future women. Recommendations include informed consent should be 
tailored, recognising individual differences in the desire for information. For instance the 
time individuals need to make consent decisions varies, as do their desires to consult 
with family before agreeing.  
 
Introduction 
Randomised controlled trials (RCTs) are considered the most rigorous method for 
determining the efficacy of treatment. Issues regarding the randomisation of pregnant 
women have been identified as needing special consideration (Mohanna, 1997), 
(Mohanna and Tunna, 1999),  (Lupton and Williams, 2004). Women undoubtedly feel 
responsible for the child they carry to the extent that they often modify their habits and 
lifestyle during pregnancy. Pregnancy may affect their ability to make free choices: they 
may feel bound to accept interventions that might benefit the unborn child which they 
would rather decline for themselves, or they may refuse treatment for themselves in 
case it should harm the baby. Given that increasing numbers of women are being 
approached to participate in trials, it is surprising that there is little research relating 
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specifically to pregnant women’s experiences of participating in trials (Baker et al., 
2005).     
 
The broad aim of the QUOTE (Qualitative Understanding of Trial Experience) Study 
was to provide insight into pregnant women’s experiences of participating in a large 
multi-centre randomised controlled trial – the Magpie Trial. This paper presents data 
from one aspect of participation explored in the QUOTE Study, namely, the process of 
decision-making around whether or not to join the trial.  
 
 
The Magpie Trial 
The Magpie Trial was a randomised trial of prophylactic anticonvulsants for women with 
severe pre-eclampsia. The trial recruited 10,141 women from 33 countries and 
demonstrated that magnesium sulphate more than halves the risk of eclampsia (Altman 
et al., 2002), without an increase in risk of death or neurosensory disability for the child 
by age 18 months (Magpie, 2007a), or in maternal death or serious morbidity potentially 
related to pre-eclampsia for the mother (Magpie, 2007b).    
 
Women were eligible for the trial if they had pre-eclampsia (hypertension plus 
proteinuria), there was clinical uncertainty about whether to use magnesium sulphate, 
and they had either not yet given birth or were 24 hours or less postpartum. For many 
women, developing pre-eclampsia is an unexpected and very difficult experience. Due 
to its unpredictability and the speed at which pre-eclampsia can develop, many women 
4 
 
offered randomisation to the Magpie Trial would likely have had little understanding of 
the disease before it became evident. The nature of the trial meant that women were 
required to give informed consent in a relatively short space of time, as prolonged 
consideration could have meant delaying the start of treatment to the point it became 
futile, and therefore ethically problematic.   
 
In the UK arm of the Magpie Trial, follow-up assessment for both women and children 
was by postal questionnaire (Magpie, 2004). Women were contacted when their 
children were approximately 2 years old to complete a questionnaire incorporating the 
Ages and Stages Questionnaires (ASQ) (Squires J, 1999). Children were considered 
‘screen positive’ for neurosensory disability if they failed the ASQ, if the ASQ could not 
be scored, or if the child passed an ASQ for a younger age group. The families of these 
children were contacted by telephone and offered a home visit for further assessment. 
Children were considered ‘screen negative’ if they passed the ASQ for their own age 
group, or for an older child. A proportion of the screen negative children were also 
offered a home visit. Methods used for follow-up in the United Kingdom are described in 
more detail elsewhere (Smyth et al., 2009b).  
 
 
Methods 
The research methods utilised in the QUOTE study were in part determined by 
procedures already in place as part of the Magpie Trial follow up. The first part of the 
QUOTE Study involved analyses of data about trial experiences which were already 
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being collected as part of the postal questionnaire sent to women involved in the UK 
follow-up study. This questionnaire included questions exploring the women’s 
experience of participating in the trial, findings from which have been reported 
elsewhere (Smyth et al., 2009a). In total, 619 women across the UK returned this 
questionnaire (81% response). The second part of the QUOTE study was designed to 
explore in greater depth the women’s experiences of joining the Magpie Trial, by 
interviewing a subgroup who completed and returned the postal questionnaire.   
 
The decision-making process around joining MAGPIE was a focal point of the interview 
schedule. Women were asked about several aspects of their decision to join the trial, 
such as how difficult or easy the decision was to make, what factors had to be taken 
into account, for example their circumstances at the time, who was with them and what 
involvement these people played, including the recruiting clinician. Women were asked 
about the timing of approach, how quickly their decision was made and about quality of 
the information received.   
 
For practical reasons women were defined as eligible for interview if they lived within a 
100 mile radius of the lead researcher in Liverpool (RMDS). Recruitment was therefore 
confined to six maternity units (three in the north west of England, two in Yorkshire and 
one in the Midlands).  They included a mixture of district general and teaching hospitals. 
In total 219 women were recruited to the Magpie Trial from these hospitals, among 
whom an 83% (n = 181) response rate to the follow-up study postal questionnaire was 
achieved. Forty-five of these 181 women were offered a Magpie follow-up study home 
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visit, as their children screened positive on the ASQ. These women were therefore also 
eligible to be interviewed for QUOTE, of whom 30 were invited to take part and 24 
agreed. Of the remaining families whose children screened negative and so were not 
eligible for a home visit (136 from the six units), 20 were selected at random and offered 
an interview, of whom 16 agreed to be interviewed for QUOTE (Figure 1).  
 
Recruitment:  
Methods of recruitment for the QUOTE Study interview depended on whether the 
women had had a home visit or not. Where a home visit was undertaken, eligible 
women (those from the six pre-selected units) were invited, at the end of the visit, to 
take part in a semi-structured interview at a later date. If they were willing, in principle, 
to consider doing so, they were given the QUOTE Study information leaflet, consent 
form and prepaid envelope. Women were not required to decide either to join or decline 
participation to the interview at the time of the follow-up study home visit. Rather, 
women were asked to consider being interviewed and, if agreeable, sign the form and 
return it in the prepaid envelope in their own time to the trial co-ordinating centre.   
 
Where no home visit was undertaken (women not eligible for a home visit as child 
screened negative on ASQ), a random sample were sent a letter, after return of their 
completed questionnaires, informing them about the QUOTE Study and inviting them to 
take part in a semi-structured interview. The Magpie Trial co-ordinating centre identified 
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these women. The women were required to actively opt into the study by considering 
and signing the consent form and returning it in the prepaid envelope in their own time.  
 
Analysis: 
Thematic analysis of the data began with formal line-by-line analysis (Morse JM, 1996). 
The next stage was to develop an index for the content (Polit DF, 2006). This involved 
creating a coding scheme, with the support of a qualitative computer analysis package 
(WinMax pro) to facilitate the analysis. This stage of the analysis related to the major 
points of interest, for example the women’s views and experiences of being recruited to 
Magpie and shared characteristics. After coding the data it was necessary to identify 
and select patterns and themes. The data were then grouped together within the 
defined themes. These steps were led by RMDS but to minimise possible interpreter 
bias and assess the plausibility and trustworthiness of the interpretation of the data, a 
sample of the interviews were themed independently by the other members of the study 
team (AJ and DE).  
 
Ethics approval for the QUOTE study was obtained from the Northwest Multicentre 
Research Ethics Committee.   
 
Findings 
Fifty women were offered an interview and ten declined: six having had a home visit and 
four not. All those who declined had been recruited to the Magpie Trial while still 
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pregnant; three of their infants were admitted to the neonatal intensive care unit after 
birth, but the children of all those whose mothers declined an interview were 
developmentally normal at follow up.   
 
The interviews were carried out at different time points after recruitment to the trial. 
Although the follow-up study aimed to assess children at two years of age, this was not 
always the case, as follow-up did not start until the Magpie Trial was complete. Hence 
the interval between randomisation and interview was greater for those women who 
were recruited early in the trial. Timing of the interviews also depended on completion of 
the follow-up study postal questionnaire, as women could only be contacted and offered 
an interview once they had completed their questionnaire and for the majority this was 
also after their follow-up study home visit (n=24). The children’s ages therefore ranged 
from two years to four years and seven months (mean time three years and one month, 
SD±9.57 months). For those women who had a home visit performed (n=24) the 
interview took place on average eight weeks later. The interviews took place from 
September 2002 to May 2004. In all but one, women were interviewed alone; for one 
woman (aged 16 at the time of recruitment) her mother was also present at the 
interview at her request and participated throughout. All interviews were performed in 
the women’s homes. They lasted between 30 and 120 minutes (mean time 50 minutes, 
SD±20.91 minutes), and all were tape-recorded with the permission of the women. 
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Sampling for the interviews was not aimed at trying to produce a statistically 
representative sample of the overall UK Magpie Trial population, but at ensuring that 
meaningful exploration could be made between different women’s experiences of the 
Magpie Trial. It was acknowledged that the women’s experiences, perceptions or recall 
of the Magpie Trial could be influenced by a number of factors. Those that were 
identified as important for consideration were: whether the resultant child had some 
degree of developmental delay or the woman herself was suffering long-term 
hypertensive problems (as it was thought possible that such women could attribute their 
problems to the trial and therefore view the study in a negative way); and pregnancy 
status at the time of recruitment (since approximately 78% of the women were recruited 
to the Magpie Trial while still pregnant this too could potentially influence their 
perceptions of the trial, given that the difficulty parents face when asked to consent to a 
research trial in which an unborn baby’s needs are to be considered).  
 
Twenty two of the women interviewed had been allocated to magnesium sulphate; and 
18 to placebo. They were aged from 16 to 39 years (mean years 29). There were some 
differences between the women interviewed compared with UK trial participants overall, 
in terms of characteristics at trial entry and outcome after randomisation (Table 1). 
Although these differences were not statistically significant, a higher proportion of 
interviewed women  were randomised to the trial postnatally (27% cf. 22%; Relative 
Risk (RR), 1.31 Confidence Interval (CI) 0.64 to 2.69); had had a caesarean section 
(76% cf. 60%; RR; 2.08 CI 0.87 to 4.97); had their labours induced (72% cf. 56%; RR; 
1.45 CI 0.77 to 2.76); and were recruited before 34 weeks gestation (38% cf. 34%; RR; 
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1.07 CI 0.52 to 2.19). Due to purposive sampling, a statistically significantly higher 
proportion of women whose children screened positive on the ASQ were interviewed 
compared with women not interviewed (83% versus 29% (RR; 2.85 CI 2.29 to 3.56)).  
 
Themes identified from the interviews relating to decision to join 
A number of major but related themes emerged regarding influences on the women’s 
decision-making:  
• Unpredictability of pre-eclampsia 
• Quality of information received  
• Role of others in the decision-making process 
• Personal benefit from trial participation 
• Perception of voluntariness of joining 
 
Unpredictability of pre-eclampsia 
It became apparent in the interviews that the clinical circumstances around trial 
recruitment were an integral part of the women’s decision-making experience. As with 
many emergency situations where treatment is needed urgently, women eligible for the 
Magpie Trial were required to make their decision to join in a very short space of time. 
Prolonged discussion could have meant delaying the start of treatment to the point 
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where it became futile. The women also expressed concerns associated with the 
seriousness of pre-eclampsia:   
 
“I had so many people around my bed, I don't really remember. I had all sorts of people 
doing all sorts of things. It’s not  like being asked to  join a trial when you are well  is  it? 
You are being asked to join a trial when you could die, basically.” [09] 
“I  recall him  telling me what  it was about but at  the  same  time  I had a paediatrician 
telling me what the odds of the baby surviving were.“ [28] 
 
However, for others their situations were different and they described a much more 
relaxed and calmer situation. It appeared from their accounts that the decision to 
participate in Magpie was relatively easy and uncomplicated: 
“She came and talked briefly to us about  it and gave us some  leaflets and then walked 
away and came back later. I said 'Yes'. It was quite a casual decision in a way. We didn't 
really agonise over it.” [04] 
“In my own mind  it was a very quick decision to make.  I had weighed up the pros and 
cons and decided yes, in probably minutes.” [13] 
 
Many women had no prior knowledge of the trial; most said they would have preferred 
to know about it prior to the point at which they had to make a decision to join; and felt 
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that had they been asked earlier in their pregnancy they would have had a better 
appreciation of its purpose: 
 
 “It may be good to be told about  it at the beginning of the pregnancy rather than you 
giving  birth  and  you  are  really  poorly  or  you  are  on  drugs  so  your  head  is  not  quite 
there.” [23] 
 
“I really don't think they should ask you when you are  in the  late stages of  labour and 
about to give birth” [30] 
 
Some women, however, did appreciate the justifiable limitations on the clinicians in 
being able to predict which women would become ill with pre-eclampsia and therefore 
eligible for the Magpie Trial. A substantial number of women interviewed acknowledged 
the difficulties associated with the provision of trial information in their particular 
circumstances and appreciated that giving information prior to the event was not 
necessarily a viable solution. There was awareness by some women that there can be 
no ‘best’ time to give this information, since earlier provision could have caused 
unnecessary worry:  
“No one knew I was going to get sick, so I could not have been asked earlier.” [31]  
“I don't know what is the way round it. They couldn't approach me when I was at home 
and nobody knew I had pre‐eclampsia” [04] 
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“It  can't be  the midwife  that  you  see  for  your antenatal  things because  they are not 
based  in the hospital. It has to be a midwife based on the delivery suite and you don't 
really know because you only go in there when it’s actually happening.” [01] 
 
Quality of information received  
Of the 40 women interviewed, 28 recalled being given the Magpie Trial information 
leaflet at the time of recruitment; eight reported they did not recall seeing the leaflet at 
any time; and four women were unsure. Nineteen women stated that they had read the 
information leaflet at the time of recruitment, although of those three felt that due to the 
difficult circumstances at the time, they could not comprehend its contents. Eight 
women reported they did not read the leaflet at the time of recruitment, though for two of 
these women their partners did. One woman did read the leaflet but only after agreeing 
to join the trial. None of the remaining women recalled seeing the leaflet. One woman 
recalled seeing a poster about the trial in the waiting area of the delivery suite prior to 
being admitted.  
 
At the time of recruitment the majority of the women (n=30) were given information 
orally by a midwife about the trial; for six this was in conjunction with an obstetrician. An 
obstetrician discussed the trial with the other ten women. Most women (n=38) recalled 
hearing about the trial for the first time while they were being cared for in a high 
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dependency unit (situated on the delivery suite), either while in labour, or having their 
labours induced, or moments before having a caesarean section. The remaining two 
women were on an antenatal ward. 
 
Women recruited to the Magpie Trial had noticeably differing requirements regarding 
the amount and content of trial information they sought. However, generally they felt 
that they did not receive adequate explanation and a sufficient level of detail about the 
trial prior to joining:  
 
“I didn't know what it was for, whether it was to bring my blood pressure down. No one 
even mentioned fitting that was completely new to me. It is the details of actually what 
it is for more than what it does.” [40] 
“I think they should have gone through it a little bit more to explain what would happen 
and a bit more information about the trial ‐ no one really said it would stop convulsions 
or  it would stop you  from developing high blood pressure,  they  just did not explain  it 
very well.” [30] 
 
Women discussed several issues regarding information provision and gave suggestions 
of what they would have liked to receive. These included: what the aim of the trial was, 
what it was hoping to find out in relation to pre-eclampsia, how the trial treatment might 
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work, the possible risks of joining, and how the trial would be administered.    
Conversely, being overloaded with information and giving explicit descriptions of their 
situation was also seen as problematic for some women. Some appeared to prefer not 
being given a full and frank description of the trial or their condition, perceiving this 
additional information as either unnecessary or creating anxiety:  
 
“It's like if I had known all that I would have been, I think my blood pressure would have 
been even higher! I think at the time the information I was given was as much as I could 
have taken in with everything else that is going on at the time.” [05] 
“I think if someone would have said when I was two months pregnant this trial is going 
on I think it would have scared me. You know ‘oh my god those terrible things could go 
wrong with me!” [08] 
 
For women who had difficulty comprehending the trial information, the language the 
midwives or obstetricians used to explain the trial appeared to be the cause of 
misunderstandings. Women stated that clinicians provided oral information that was too 
technical for them to grasp; and that the concepts used by the clinicians were often 
unfamiliar. Women wanted the information to be in clear, simple, lay language and 
presentation:  
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“I suppose if he (the doctor) had simplified it. The doctor who was telling us gave us this 
sales pitch in the words he had obviously come to use and when he hit a blank wall he 
did not know how to explain it in a more plain English way. What I had to do to make my 
decision was I had to ask him: ‘the way you have explained this trial to me, I think it is x, 
y z am I right?’ and I actually had to ask him ‘is this what you are telling me?’ I actually 
had to come up with my own way of interpreting what he said.” [03] 
 
"Not that I could really understand the doctor. It was the midwife really who explained 
it to me she explained  it sort of  in our words, you know, because doctors give you all 
these big words don't they that you don't understand?” [36]   
                           
Contrary to the assumption that clinicians would be familiar with the design and purpose 
of any trial they collaborated in and recruited patients to, a number of women in the 
QUOTE Study described instances where the recruiting clinicians appeared not to be 
familiar with some aspects of the Magpie Trial:  
 
“I knew  there was a minimum  risk of  things going wrong, but  I don't  think  they knew 
that much about  it themselves.  If they'd of been trained more on  it maybe that would 
have helped them. They were just a bit, I don't know, they just didn't give me that much 
information back.” [16] 
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“She was nice, but she did not seem to know a great deal about  it and there was not 
much information” [34] 
 
Role of others in the decision-making process 
Reassurance from attending clinicians 
The influence of the clinicians emerged as key to the women’s decision-making 
process. Their accounts demonstrated that they had considerable faith and trust in their 
clinicians, and this appeared to be a motivator to joining: 
 “I just automatically trusted them I suppose.” [15] 
 
“You trust that the doctor would not give you something that is going to give you a long‐
term problem. You have to take advice from the people who know more about  it than 
you. ” [09]                              
 
“I knew they would not give  it to you  if there was any serious risk to me or the baby. 
They would not do  it  if  there was a  serious  risk,  they were  trying  to get  rid of  it not 
produce more.” [30] 
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Role of family members  
As previously described, women eligible to join the Magpie Trial were in an emergency 
situation, sometimes life-threatening. As with most hospital emergency situations, 
partners, family members or friends are able to be with the patient throughout the critical 
period. The women in the QUOTE Study were therefore asked who was with them at 
the time they were approached about the Magpie Trial and what influence, if any, this 
person(s) had on their decision to join. Most women (32) had a support person with 
them when they were asked to consider joining the Magpie Trial: this was usually their 
partner, but sometimes an additional family member. It was apparent however, that 
these partners and family members did not actively participate in the decision to join 
Magpie; in the main, the decision rested with the women themselves:  
 
“My husband was there. I would think though that most women make the decision on 
their own, the way that my husband  looked at  it  is  it  is not being administered to him 
it's my body so it's my decision.” [12] 
“It was my decision. I think my partner knew at the end of the day  it was my decision. 
Yes it was just very much my decision.” [13] 
 
Some women, however, did acknowledge that their partner or support person played a 
part – even if relatively small - in their decision to join Magpie:  
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“I honestly believe he had input, because he does have an input, but it was my decision 
to take.” [39] 
“I  just  wanted  a  second  opinion  from  my  friend.  I  just  said  what  do  you  think?  I 
remember her having a look at the leaflet.” [31] 
 
For the eight women who were approached to join the trial while on their own, it was 
apparent from their responses that at the time of recruitment their partners had only 
recently left their side and being asked to join the trial while alone did not seem 
problematic: 
 
“I just did it on my own. They asked me did I want to discuss it with my partner before I 
started the trial but to me it was my choice, it was me that was carrying the baby, it was 
me that was going through it.” [36] 
“I was  on my  own,  personally  it  didn't  bother me.  It might  bother  some  people  but 
personally it didn't bother me. Later on he fully agreed. He said whatever you decide is 
fine.” [26] 
In summary, then, although partners and family members were often present they did 
not, in the majority of cases, play a significant role in the decision-making process. It 
was the women themselves who ultimately made the decision to join Magpie. The 
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reasons given for this were that it was the woman herself who would be receiving the 
trial treatment and it was therefore her right, ultimately, to choose.  
 
Personal benefit from trial participation 
Some women saw joining the Magpie Trial as a vehicle for obtaining the ‘active’ 
treatment - and for getting a drug that they would not otherwise receive, but which had 
been suggested to them by the recruiting clinicians as one that would prevent them from 
experiencing a seizure. As a result they believed participation to be beneficial to them: 
“The way  it was explained  I got the  impression that they had already got an  idea that 
magnesium  sulphate  was  of  benefit.  I  probably  hoped  that  I  would  have  got  the 
magnesium sulphate. I hope I do not get the dummy if you like. I hope I do get it. [03] 
 
“They explained  that  the magnesium  sulphate would bring my blood pressure down, 
and even though I was told one would be a dummy, I still did not click that I could have a 
dummy. I just thought yes I will have it” [24]  
 
There was limited appreciation of any potential for harm to either the woman or her 
unborn baby; and a clear belief among the women that magnesium sulphate was 
beneficial. Women also appreciated that irrespective of which trial treatment they were 
randomised to, they would not be denied magnesium sulphate if this was clinically 
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indicated, i.e. when having an eclamptic convulsion. This made some women 
unconcerned regarding the implications of joining: 
 
“I asked if I did get worse what would happen and she said we will take you off this and 
we would give you magnesium sulphate because it has been tested and that will help if 
you do get eclampsia.” [11] 
“She said  in America they gave magnesium sulphate routinely and yet  it wasn't proven 
in  this  country  and  it would  prevent  if  not  a  first  fit  then  it would  certainly  prevent 
subsequent fits and that's how it was explained to me.” [37] 
 
perceived voluntariness of joining  
The responses from some women clearly showed that although in a clinically difficult 
situation, they did not feel pressurised by the clinician to take part in Magpie and 
understood the voluntary nature of joining: 
 
“The midwife  in the delivery room said  it was my choice and there  is no pressure. She 
explained there was no pressure and they would not come back to me and ask again” 
[16] 
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“I did have a choice. I definitely had a choice I was not forced into it. It was completely 
my choice to take part.” [19] 
 
Some women discussed the value of research per se and thought it was desirable to 
take part, even a person’s duty.  Participating also improved their personal experience:  
“I think  if you are really kind and you think about other people then you should, then 
you’re  thinking  about  the welfare  of  other  people,  no  I  think  you  should  help  other 
people out.” [22] 
 
“I felt a bit honoured. I had gone through something that other people wanted to learn 
about and I am all for research. I mean  if people can stop this happening then I am all 
for it.” [11] 
 
 “I think it’s good that research is done and I think if we didn't take part in research then 
we wouldn't have all these drugs so I do believe in research. I am glad I did take part in.” 
[25] 
Willingness to participate also seemed to rest on the women’s awareness that they 
could withdraw from the trial at any time. For four women who volunteered this 
information it appeared this positively influenced their decision to join.    
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Discussion  
 
Amount and timing of information  
During the interviews most of the women described the time of recruitment as 
immensely frightening, stressful, and even very traumatic. Much of this was related to 
the unexpected and sudden occurrence of severe pre-eclampsia, For some women, 
however, it appeared the decision was made quickly because of its ease: the decision 
appeared casual even, a decision that was not particularly agonised over.  
 
Due to the features of pre-eclampsia clinicians were unable to identify who would and 
would not be affected by the condition in advance, so the provision and timing of 
information about possible treatments and potential clinical trials relating to pre-
eclampsia was challenging. Although the majority of women were reasonably satisfied 
with the level of detail of information received, it was evident the timing of information 
provision was problematic. Most indicated that had they been told earlier in their 
pregnancy they would have found the decision to join less stressful. However, some 
said they would not have wanted to know about the trial earlier and made comments to 
the effect that knowing about the trial before becoming eligible would have caused them 
unnecessary worry.  
Our findings are similar to those of Mohanna (Mohanna and Tunna, 1999) in their study 
of pregnant women’s decisions to withhold consent to a preterm labour trial. In that 
study, most of the women had not considered they were at risk of preterm labour and 
therefore could not see the relevance of being told early about the trial. Vernon et al 
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(Vernon et al., 2006) have outlined how informing women early in pregnancy can bring 
about tension between promoting pregnancy and labour as a normal physiological 
process and flagging up the possibility of experiencing an adverse event.  
 
Self-interest is a key motive for participating  
Research participants in randomised trials often believe that participation will result in 
better treatment. This ‘trial effect’, also known as the ‘Hawthorn effect’, has been 
explored in at least four systematic reviews (Stiller, 1994),  (Braunholtz et al., 2001), 
(Peppercorn et al., 2004), (Vist Gunn et al., 2008). Although their conclusions differ 
regarding as to the extent to which trials actually have benefit, all these authors agree 
that it is more likely that trials have a positive than negative effect on the outcomes for 
those taking part.   The findings from the QUOTE Study are consistent with this as the 
majority of women agreed to participate in Magpie primarily because they believed 
participation would result in benefit to either themselves or their baby. Major motivating 
factors for participation fell into three broad categories: self-benefit (trial might help treat 
pre-eclampsia), benefit to their child (treatment might minimise the associated risks of 
pre-eclampsia to the unborn baby) and altruism (participation might help future women 
or is for the good of medical science). In most cases, women identified more than one 
benefit; and just five of the 40 women interviewed identified altruism exclusively as their 
reason for taking part.  
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The majority of women expressed a preference for the active drug, magnesium 
sulphate, and very few voiced concerns about any possibility of risk to either themselves 
or their unborn baby. In a number of accounts it appeared the recruiting clinician had 
expressed the hope that the woman would be randomised to magnesium sulphate, 
because he/she was already convinced of its benefit. This is reflective of the fact that 
although at the time of the trial there was ‘collective equipoise’ (uncertainty within the 
medical community as a whole over which treatment is best) (Freedman, 1987)  
regarding the benefits of magnesium sulphate, some clinicians were not in ‘personal 
equipoise’. This finding of lack of personal equipoise by recruiting clinicians supports the 
results of other studies (Canvin and Jacoby, 2006), and is perhaps not surprising given 
that a fundamental ethical perception of research is that the well-being of an individual 
must never be sacrificed for some perceived greater collective good.  
 
Influences on participation 
Trust in the midwife or obstetrician was another important element in the recruitment 
decision. Some women relied on the confidence they had in the recruiting clinician: 
trusting that s/he would not expose them or their babies to anything risky. However, 
health professionals involved in Magpie had dual roles both as clinician and as 
researcher. As clinicians, their objective was to apply existing knowledge in order to 
achieve the best possible outcome of each woman. As researchers, their objective was 
to gain further knowledge for the greater good and in the case of Magpie to leave some 
treatment decisions (administration of magnesium sulphate) to a chance process. In this 
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type of situation care and research are so closely interlinked that it is often impractical 
and impossible not to intermingle the two. Women may have expected their obstetrician 
or midwife to have acted first as clinicians whose primary concern was their physical 
well-being and care. The clinicians’ dual role as researcher may have appeared 
irrelevant to the clinical decision to be made.  
 
Although some women sought the opinion of family members and friends, it was 
apparent they had little involvement or influence on the woman’s decision. Many women 
emphasised that their partner played a role in providing a second opinion, as someone 
to confer with. However, women dismissed the idea that their relatives or friends were in 
the position to influence their decision - either because they were distressed too, or 
because they were not able to interpret trial details any better than the women 
themselves. Most women said they made the decision to join independently; and the 
family being present was neither required nor a substantial influence.  
 
The study findings demonstrate some of the difficulties women experience when 
considering joining a trial in the perinatal period. The general implication for practice is 
that procedures are needed that can improve the design and conduct of randomised 
trials and therefore ultimately enhance the experience for future women. We 
recommend that when explaining the trial clinicians should use simple language. The 
consent process should include particular attention to the distinctions between 
procedures performed as part of the trial and procedures performed as part of routine 
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clinical practice. Returning the results should be done in a careful and well-planned 
manner that provides comprehensive support; with an invitation to contact the 
researcher for a verbal discussion if the participant wishes. Researchers should budget 
for the costs of returning results including maintaining contact with research 
participants. Methods to disseminate the results should be included in research 
protocols. Offering unblinding of treatment arms on completion of the trial should be 
made available. Similar to the provision of results this needs to be well planned and 
done carefully. Procedures need to provide full support to participants, with available 
contact with the researchers for verbal discussion if they wish. 
 
 
Conclusion 
Despite widespread acceptance of the potential benefits of randomised controlled trials 
of clinical care in pregnancy (Hofmeyr JG, 2008), little attention has been paid to 
participants’ reactions to and understanding of their trial experience.  This study has 
attempted to shed some light on decisions about joining and taking part in the Magpie 
Trial, as experienced by the women who participated in it. The data presented give 
valuable insights into the women’s experiences of decision-making about participation.  
It is undisputed that clinical research is important for the continued development of 
healthcare and the wellbeing of society. The QUOTE Study increases understanding of 
the experiences of those participating in a randomised controlled trial. As more data of 
the type reported here accumulate, clinicians and researchers will have the option to 
modify research strategies to reflect participants’ real concerns and needs. 
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619 (81%) returned UK children & women’s questionnaire  
                   - 181 (29%) from the 6 selected maternity units  
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Figure 1 Women eligible for qualitative interview 
Screened positive children 
(from the 6 selected maternity units) 
(n=45) 
Screened negative children
(from the 6 selected maternity units) 
                       (n=136) 
Women invited for interview 
 (n= 20) 
Women invited for interview 
(n=30) 
 
 
Women interviewed 
(n=24) 
 
Women interviewed 
(n=16) 
Home visit performed 
(n=45) 
No home visit performed
                     (n=136) 
Declined interview 
(n=6) 
Declined interview
(n=4) 
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     Interviewed  
 
Not interviewed 
       
   n =40 
 
   (%) 
 
  n=579 
 
   (%) 
Characteristics of women         
Primiparous      30     (75)   423        (73) 
Multiple pregnancy  4  (10)  25  (4) 
Age (less than 20 years)  2  (5)  46  (8) 
Severe pre‐eclampsia  23  (57)  261  (45) 
Imminent eclampsia  9  (22)  157  (27) 
Delivered before trial entry  11  (27)  127  (22) 
Randomised magnesium sulphate  22  (55)  281  (49) 
Outcome after randomisation – maternal         
Eclampsia  0  (0)  4  (<1) 
Other severe morbidity         
Admission to high dependency care  36  (90)  485  (84 
On trial treatment more than 12 hours  31  (78)  486  (84) 
Side effects  10  (25)  102  (18) 
Randomised before delivery  29    448   
Caesarean section  22  (76)  269  (60) 
Induction of labour  21  (72)  250  (56) 
Outcome – Infant         
≤34 weeks at trial recruitment  11  (38)  152  (34) 
Admitted to neonatal unit  17  (59)  308  (68) 
ASQ Screen positive*  24  (83)  130  (29) 
         
* Statistically significant when comparing those interviewed with those not 
Table 1 Characteristics of women interviewed and not interviewed 
